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Abstract: Wilms tumor (WT) is the most common childhood renal cancer. Recent findings of
mutations in microRNA (miRNA) processing proteins suggest a pivotal role of miRNAs in WT
genesis. We performed miRNA expression profiling of 36 WTs of different subtypes and four
normal kidney tissues using microarrays. Additionally, we determined the gene expression profile
of 28 of these tumors to identify potentially correlated target genes and affected pathways. We
identified 85 miRNAs and 2107 messenger RNAs (mRNA) differentially expressed in blastemal WT,
and 266 miRNAs and 1267 mRNAs differentially expressed in regressive subtype. The hierarchical
clustering of the samples, using either the miRNA or mRNA profile, showed the clear separation of
WT from normal kidney samples, but the miRNA pattern yielded better separation of WT subtypes.
A correlation analysis of the deregulated miRNA and mRNAs identified 13,026 miRNA/mRNA
pairs with inversely correlated expression, of which 2844 are potential interactions of miRNA and
their predicted mRNA targets. We found significant upregulation of miRNAs-183, -301a/b and
-335 for the blastemal subtype, and miRNAs-181b, -223 and -630 for the regressive subtype. We
found marked deregulation of miRNAs regulating epithelial to mesenchymal transition, especially in
the blastemal subtype, and miRNAs influencing chemosensitivity, especially in regressive subtypes.
Further research is needed to assess the influence of preoperative chemotherapy and tumor infiltrating
lymphocytes on the miRNA and mRNA patterns in WT.
Keywords: miRNA; Wilms tumor; blastemal; regressive
1. Introduction
Wilms tumor (WT), or nephroblastoma, is the most common childhood renal tumor with an
overall survival of more than 90% [1]. Nevertheless, 13% of all patients develop a relapse within the
first two years after diagnosis [2]. In Europe, the International Society of Paediatric Oncology (SIOP)
defined pre-operative chemotherapy as standard treatment, based solely on imaging studies [3,4].
Postoperative treatment depends on the local tumor stage and histological subtype according to the
revised Stockholm classification [5]. The Children’s Oncology Group (COG) in North America also
uses molecular markers for further risk stratified treatment, namely the loss of heterozygosity (LOH)
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for chromosomes 1p and 16q that is associated with an inferior outcome in a small subgroup of patients
with WT [6–9]. The response to preoperative treatment plays an important role in SIOP. A remaining
blastema after chemotherapy is a high risk factor and these patients need the same intensive treatment
as patients with diffuse anaplasia [10].
MiRNAs are a class of small, endogenous, non-coding ribonucleic acids (RNAs) that are
involved in the regulation of multiple physiologic processes, including apoptosis, proliferation, cell
differentiation and are implicated in the pathogenesis of various diseases. The deregulation of miRNAs
has been reported for many cancer types, including WT [11,12]. They can function as tumor suppressors
and oncogenes at the same time [13–15]. Recent studies implicate that down- or upregulation of certain
miRNAs may be the cause of non-responders to therapy or sensitizers to treatment, respectively [16,17].
In addition, circulating miRNAs have diagnostic and prognostic potential [18–22].
Recent evidence points toward a major role of miRNAs in WT genesis [23–27]. In a previous
study we were able to determine treatment-independent miRNA signatures in the blood of patients
with WT compared to controls [28]. There is also evidence for miRNAs expressed in WT tumors as
markers for chemo-responsiveness in WT blastemas [29].
In the current study we assessed the tissue-based miRNA and gene expression profile of 36 WTs
and four normal kidneys to identify miRNAs and genes differentially expressed in WT and in WT
subtypes that might aid the development of a subtype specific miRNA biomarker.
2. Results
2.1. Deregulated miRNA Expression in Wilms Tumor (WT) Compared to Normal Tissue
We measured the expression of 1205 miRNAs by using Agilent microarrays based on miRBase
version 16. Following background correction and quantile normalization, the miRNA expression
profiles of 36 WTs and four normal kidney samples were used to identify miRNAs differentially
expressed between the main WT subtypes, including regressive WT, mixed WT, and blastemal WT,
and normal kidney samples. Unsupervised hierarchical clustering using the miRNAs with highest
variance in our set revealed three main groups (Figure 1). One cluster contained 10 of the 11 regressive
WT and two samples of mixed WT subtype, the second contained all four normal kidney samples
and one blastemal WT, and the third contained the remaining 14 blastemal WTs, four mixed WTs, one
regressive WT and four samples with other subtypes (stromal, epithelial, diffuse and focal anaplasia,
one sample each). The one blastemal tumor sample that clusters together with the normal kidneys
may have had a low percentage of tumor cells, therefore the miRNA profile might be masked by
more abundant normal cells in the sample. In general, this analysis shows that tissue-borne miRNAs
allow classification not only between normal kidneys and the WT, but also between regressive and
blastemal WTs.
Next, we performed unpaired t-tests to identify those miRNAs that show a differential abundance
in all WTs compared to normal kidneys, and in blastemal and regressive subtypes, each also compared
to a normal kidney. We considered those miRNAs as significantly differentially expressed that
showed a fold change of >2 between WT samples and controls, and a p-value <0.05 in an unpaired
t-test. In total, we identified 96 miRNAs that were significantly deregulated in all WT samples
compared to controls (30 up in WT, 66 down in WT). An expression analysis of WT subtypes revealed
85 significantly deregulated miRNAs in the blastemal subtype (30 upregulated and 55 downregulated
miRNAs) and 266 significantly deregulated miRNAs in the regressive subtype (131 upregulated and
135 downregulated miRNAs). The 15 most up- and downregulated miRNAs for each blastemal
and regressive subtype, and for all WTs irrespective of subtype, are given in Table 1 (the full list of
deregulated miRNAs is given in Supplemental Table S1). These data are largely in agreement with
the clustering analysis. There is a different overall miRNA expression pattern in blastemal WTs as
compared to regressive WTs, with blastemal WTs showing more downregulated miRNAs than the
upregulated, while the regressive WTs show a more balanced number of up- and down-regulated
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miRNAs. The difference in miRNA expression in both subtypes also shows in the number of specifically
expressed miRNAs, with 27 miRNAs deregulated solely in the blastemal subtype, and 177 miRNAs
deregulated only in the regressive subtype as seen in Figure 2. There were also 49 miRNAs, which
were found in all three comparisons, including three members of the miR-320 family, miR-1207-5p and
miR-483-3p (upregulated) and 43 downregulated miRNAs, including several members of the miR-200
family, miR-141, and miR-429 (Figure 2).
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Figure 1. Unsupervised hierarchical clustering (Euclidian distance, complete linkage) of the 40 samples
based on expression of the 50 with highest variance. The heatmap shows microRNAs with high
expression in red, miRNAs with low expression in green. The red lines indicate three main clusters
of samples.
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Table 1. Deregulated miRNAs in Wilms tumors (WT) tissue compared to normal kidneys. 
15 Most Downregulated miRNAs in WT Subtypes Compared to Normal Kidneys 
Blastemal Regressive All WT 
miRNA FC 1 miRNA FC 1 miRNA FC 1 
miR-194 48.95 miR-30a 143.28 miR-200a 46.47 
miR-204 43.09 miR-194 64.67 miR-194 46.22 
miR-200a 33.71 miR-200a 38.3 miR-204 36.81 
miR-192 33.2 miR-204 36.5 miR-200b 35.38 
miR-429 29.99 miR-30a * 34.58 miR-141 31.93 
miR-215 25.52 miR-200b 31.58 miR-192 28.55 
miR-200c 24.62 miR-192 26.64 miR-429 28.46 
miR-200b 24.39 miR-1973 26.05 miR-215 24.02 
miR-30 a* 18.33 miR-141 24.1 miR-1973 22.35 
miR-514 15.77 miR-4284 23.57 miR-200c 21.46 
miR-141 14.47 miR-200c 21.44 miR-30a * 18.81 
miR-1973 12.75 miR-429 20.79 miR-30a 16.95 
miR-30a 11.46 miR-215 19.34 miR-514 9.56 
miR-138 7.57 miR-30b 18.61 miR-30c-2 * 7.06 
miR-30c-2 * 6.16 miR-26a 14.51 miR-30c 7.01 
15 Most Upregulated miRNAs in WT Subtypes Compared to Normal Kidneys 
Blastemal Regressive All WT 
miRNA FC 1 miRNA FC 1 miRNA FC 1 
miR-199b-5p 7.87 miR-3149 25.05 miR-483-3p 8.11 
miR-130b 6.16 miR-595 23.95 miR-34a 5.47 
miR-335 5.50 miR-1290 23.61 miR-1207-5p 5.18 
miR-483-3p 4.61 miR-32 * 20.63 miR-199b-5p 4.58 
miR-183 4.48 miR-1225-5p 20.55 miR-1249 3.81 
miR-301b 4.00 miR-3148 19.09 miR-130b 3.80 
miR-301a 3.88 miR-1228 * 15.87 miR-1202 3.66 
miR-34b * 3.79 miR-670 15.06 miR-320c 3.59 
miR-34a 3.70 miR-4270 13.80 miR-1225-5p 3.50 
Figure 2. Venn diagram of (A) up- and (B) down-regulated miRNAs in Wilms tumors (WT) compared
to normal kidneys.
Table 1. Deregulated miRNAs in Wilms tumors (WT) tissue compared to normal kidneys.
15 Most Downregulated miRNAs in WT Subtypes Compared to Normal Kidneys
Blastemal Regressive All WT
miRNA FC 1 miRNA FC 1 miRNA FC 1
miR-194 48.95 miR-30a 143.28 miR-200a 46.47
miR-204 43.09 miR-194 64.67 miR- 4 46.22
miR-200a 33.71 miR-200a 38.3 miR-204 36.81
miR-192 33.2 miR-204 36.5 miR-200b 35.38
miR-429 29.99 miR-30a * 34.58 miR-141 31.93
miR-215 25.52 miR-200b 31.58 miR-192 28.55
miR-200c 24.62 miR-192 26.64 miR-429 28.46
miR-200b 24.39 miR-1973 26.05 miR-215 24.02
miR-30a * 18.33 miR-141 24.1 miR-1973 22.35
miR-514 15.77 miR-4284 23.57 miR-200c 21.46
miR-141 14.47 miR-200c 21.44 miR-30a * 18.81
miR-1973 12.75 miR-429 20.79 miR-30a 16.95
miR-30a 11.46 miR-215 19.34 miR-514 9.56
miR-138 7.57 miR-30b 18.61 miR-30c-2 * 7.06
miR-30c-2 * 6.16 miR-26a 14.51 miR-30c 7.01
15 Most Upregulated miRNAs in WT Subtypes Compared to Normal Kidneys
Blastemal Regressive All WT
miRNA FC 1 miRNA FC 1 miRNA FC 1
miR-199b-5p 7.87 miR-3149 25.05 miR-483-3p 8.11
miR-130b 6.16 miR-595 23.95 miR-34a 5.47
miR-335 5.50 miR-1290 23.61 miR-1207-5p 5.18
miR-483-3p 4.61 miR-32 * 20.63 miR-199b-5p 4.58
miR-183 4.48 miR-1225-5p 20.55 miR-1249 3.81
miR-301b 4.00 miR-3148 19.09 miR-130b 3.80
miR-301a 3.88 miR-1228 * 15.87 miR-1202 3.66
miR-34b * 3.79 miR-670 15.06 miR-320c 3.59
miR-34a 3.70 miR-4270 13.80 miR-1225-5p 3.50
miR-18a 3.58 miR-2278 13.23 miR-320d 3.34
miR-199a-3p 3.23 miR-1207-5p 13.21 miR-4270 3.25
miR-342-3p 3.08 miR-1306 13.07 miR-4281 3.01
miR-181c * 2.97 miR-4281 12.19 miR-320e 2.96
miR-1207-5p 2.95 miR-1246 11.66 miR-296-5p 2.67
miR-342-5p 2.82 miR-574-5p 10.91 miR-335 2.63
1 FC = Fold change; * indicates miRNA-star sequence.
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2.2. Reverse Transcription Quantitative Realtime PCR (RT-qPCR) Validation of the miRNA Expression in WT
Compared to Normal Tissue
For validation of the array data, we performed reverse transcription quantitative PCR (RT-qPCR)
of five selected miRNAs in the same sample set that was used for array analysis (Table 2). These
miRNAs were selected based on their differential expression in blastemal (miR-181b, -223, -320a,
-485-3p) or regressive (miR-143) subtype in the array data and their previous association with either
Wilms tumors or chemosensitivity. In detail, the miRNA miR-181b showed an upregulation with a fold
change of 3.2 in a regressive WT vs. a normal kidney in the array analysis, and an upregulation with a
fold change of 6.28 in the RT-qPCR analysis. Each of these analyses was statistically significant. The
direction of deregulation of the miR-181b was also confirmed for the comparison between blastemal
WT vs. a normal kidney: the array analysis showed an upregulation with a fold change of 1.2, and
the RT-qPCR analysis showed a significant upregulation with a fold change of 3.52. Likewise, there
was a confirmation of the upregulation of miR-223 in a regressive WT vs. a normal kidney with a
significant fold change of 6.32 in the array analysis and of 60.34 in the RT-qPCR analysis. A significant
upregulation was found for the miR-485-3p analysis, with a fold change of 3.97 in the array and a fold
change of 11.11 in the RT-qPCR analysis in a regressive WT vs. a normal kidney. The upregulation of
miRNA-320a in a blastemal WT vs. a normal kidney was also found both in the array and the RT-qPCR
analysis, with significant fold changes of 2.69 and 2.08, respectively. MiR-143 was the only selected
miRNA that showed a high and significant fold change in the array analysis, but not in the RT-qPCR
analysis. Notably for miR-181b, miR-223, miR-485-3p and miR-320a, the direction of deregulation was
also confirmed for the general comparison between WT and normal controls, with all four miRNAs
upregulated both in the array and the RT-qPCR analysis.
Table 2. Reverse transcription quantitative realtime PCR (RT-qPCR) validation results.
miRNA
Fold Change Direction of Regulation Significance (p-Value) Comparison
Array RT-qPCR Array RT-qPCR Array RT-qPCR
miR-181b
1.21 3.52 up up ns 1 3.40 ˆ 10´4 blastema vs. normal
3.20 6.28 up up 0.021 0.006 regressive vs. normal
2.41 5.88 up up ns 7.45 ˆ 10´8 all WT vs. normal
miR-223
1.74 1.99 up up ns 0.273 blastema vs. normal
6.32 60.34 up up 0.027 0.002 regressive vs. normal
2.10 8.97 up up ns 0.008 all WT vs. normal
miR-320a
2.69 2.08 up up 0.013 0.002 blastema vs. normal
1.82 3.64 down up ns 0.026 regressive vs. normal
1.11 2.85 up up ns 4.11 ˆ 10´5 all WT vs. normal
miR-485-3p
1.02 2.20 up up ns 0.065 blastema vs. normal
3.97 11.11 up up 0.001 0.023 regressive vs. normal
2.02 3.62 up up 0.021 0.007 all WT vs. normal
1 ns = not significant.
2.3. Deregulated mRNA Expression in WT Compared to Normal Tissue
We determined the mRNA expression profile using SurePrint G3 Human Gene Expression
microarrays. In total, we analyzed the mRNA expression of 28 WTs and four normal kidney samples
also used for the miRNA analysis. The WT samples included five regressive WTs, 15 blastemal WTs,
four mixed WTs, one stromal WT, one epithelial WT, one diffuse anaplastic WT and one focal anaplastic
WT. First, we used unsupervised hierarchical clustering depending on the expression of the 50 genes
with highest variance to identify groups of tumors with similar gene expression patterns (Figure 3).
One cluster contained all four normal kidney samples and the one blastemal tumor that clustered
together with the normal kidneys in the miRNA analysis further supporting the hypothesis of low
tumor cell content of the sample. As for the remaining groups, the clustering did not separate the
different subgroups as clear as in the miRNA analysis. In general, mRNAs allowed classification only
between a normal kidney and a WT, but not between regressive and blastemal WTs.
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Figure 3. Unsupervised hierarchical clustering (Euclidian distance, complete linkage) of the 32 samples
based on expression of the 50 mRNAs with highest variance. The heatmap shows mRNAs with high
expression in red, mRNAs with low expression in green. The red line indicates two main clusters
of samples.
For the identification of differentially expressed genes, we compared mRNA expression levels in
blastemal, regressive and all WTs, combined with the gene expression level in normal kidneys using
unpaired t-tests. Similar to the miRNA analysis, genes with a significant p-value in the t-test (p < 0.05)
and a fold change of >2 were considered as significantly differentially expressed. A total of 2010
genes were significantly deregulated in all WTs vs. normal kidneys, including 1311 downregulated
and 699 upregulated genes. With respect to subtypes, we found 2107 deregulated genes (764 up,
1343 down) in blastemal subtype vs. controls, and 1267 deregulated genes (234 up, 1033 down) in
regressive subtype vs. controls. The Venn diagram in Figure 4 shows that 100 upregulated and
815 downregulated genes were common in the three comparisons. Subtype-specific deregulation was
found for 256 genes (142 up, 114 down) in the blastemal and 286 genes (128 up, 158 down) in the
regressive subtype. A list of all deregulated mRNAs is included in Supplemental Table S2. In general,
we found an increased number of miRNAs and mRNAs each downregulated in WTs as compared to
the normal tissues, most notably in blastemal WTs vs. normal kidneys.
2.4. Relation of mRNA and miRNA Expression
To further understand the relationship between miRNA and mRNA changes, and to specifically
identify potentially relevant miRNA-mRNA target interactions, we computed the Pearson correlation
coefficient for each miRNA/mRNA pair using the 96 deregulated miRNAs and 2010 deregulated
mRNAs as input. In total, we found 13,026 miRNA-mRNA-pairs (1877 genes and 88 miRNAs) with
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inverse correlated expression (see Methods section and Supplemental Table S3). Of these potential
interactions, 2844 are listed in miRWalk as predicted (854 genes and 70 miRNAs) and 36 thereof are
listed in miRTarBase as validated (33 genes and 14 miRNAs). To identify the underlying pathways
affected by potentially miRNA-regulated genes, we performed an overrepresentation analysis using
all 1877 detected genes in GeneTrail [30]. The kyoto encyclopedia of genes and genomes (KEGG)
pathways significantly enriched for deregulated genes are displayed in Table 3. We found three
main groups of KEGG pathways: (i) metabolism: including multiple amino acid, drug and fatty acid
metabolism pathways; (ii) signaling molecules and pathways: including “cell adhesion molecules” and
Calcium- and PI3K-Akt signaling; and (iii) organismal systems pathways: including “Proximal tubule
bicarbonate reclamation”, “Peroxisome proliferator-activated receptors (PPAR) signaling pathway”
and “Endocrine and other factor-regulated calcium reabsorption”.
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Table 3. Kyoto encyclopedia of genes and genomes (KEGG) pathways enriched for potential target
genes of deregulated miRNAs in WTs.
Group of Pathways Individual Pathways
Metabolism
Tryptophan etabolism
Starch and sucrose metabolism
Retinol metabolism
Phenylalanine metabolism
Pentose and glucuronate interconversions
Metabolism of xenobiotics by cytochrome P450
Metabol c p thways
Histidine metabolism







Ascorbate and aldarate metabolism
Arginine and prolin metabolism
Arachidonic acid metabolism
Alanine, aspartate and glutamate metabolism
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Table 3. Cont.
Group of Pathways Individual Pathways
Signal transduction and signaling molecules
Calcium signaling pathway
Cell adhesion molecules (CAMs)







Organismal systems (immune, endocrine, digestive,
excretory, sensory)
Renin-angiotensin system
Proximal tubule bicarbonate reclamation





Endocrine and other factor-regulated calcium reabsorption






2.5. Chromosome Mapping of Deregulated miRNAs and mRNAs
To identify chromosome regions that are enriched for deregulated miRNAs, we performed a
GeneTrail overrepresentation analysis (Table 4) [30]. We found significant enrichments of miRNAs
downregulated in blastemal WTs vs. controls on chromosome 1 (11 precursors). MiRNAs that were
downregulated in the regressive subtype were significantly enriched on chromosome X (31 precursors).
Likewise, miRNAs that were downregulated in all WTs were enriched on both chromosome 1 and
X. A significant enrichment of mRNAs downregulated in all WTs was found for mitochondrial
DNA. There was no significant enrichment on any chromosomal location for upregulated genes or
upregulated miRNAs.
Table 4. Chromosomal enrichment analysis of miRNAs and genes downregulated in WT tissue.
Chromosome (chr)
miRNA
Blastemal Regressive All WT
Expected Observed p Expected Observed p Expected Observed p
Chr 1 3.97 11 0.01 – – – 5.09 12 0.02
Chr X – – – 12.43 31 <0.001 5.76 18 <0.001
Chromosome (chr)
Genes
Blastemal Regressive All WT
Expected Observed p Expected Observed p Expected Observed p
Chr 4 40.55 61 0.01 – – – 40.71 64 0.002
Mitochondrial genome 0.71 11 <0.001 0.55 9 <0.001 0.71 9 <0.001
3. Discussion
There is growing evidence that miRNAs play a major role in Wilms tumor genesis. Differential
miRNA expression in WTs seems to be at least in part due to specific mutations that are mostly in
the RNA binding domains of enzymes needed for the maturation of miRNAs, specifically drosha
ribonuclease III (DROSHA), dicer 1 ribonuclease III (DICER1) and DGCR8 microprocessor complex
subunit (DGCR8) [25–27,31,32]. Mutations in the DICER1 enzyme induce decreased abundance of
mature 5p-miRNAs through the strand-specific inhibition of miRNA cleavage, whereas mutations in
the DROSHA enzyme lead to a global decrease of canonical miRNAs in the mutated tumors [26,31].
Int. J. Mol. Sci. 2016, 17, 475 9 of 17
Most interestingly, the DROSHA and DGCR8 mutations show a higher prevalence in WTs with
blastemal histology [25,27].
In our current study, we found evidence for an overall altered miRNA expression pattern between
different WT subtypes, most notably between regressive and blastemal WTs. The molecular difference
between these two subtypes also shows in the number of deregulated miRNAs, which is three times
higher in the regressive subtype as compared to the blastemal subtype (266 vs. 85). Likewise, the overall
direction of deregulation is different between the two subtypes: approximately 2/3 of deregulated
miRNAs downregulated in blastemal subtypes compared to normal kidneys in contrast to a similar
number of up- and down-regulated miRNAs in the regressive subtype. These findings are in line with
the abovementioned preferential loss of mature miRNA expression in WTs with blastemal histology due
to the mutations in the miRNA processing enzymes. As for the biological explanation of the increased
number of deregulated miRNAs in regressive compared to blastemal subtypes, and also for the more
balanced ratio of up- and down-regulated miRNAs in regressive tumors, it is legitimate to speculate
that these observations might be due to the increased presence of immune cells in this subtype.
Several specific miRNAs have already been associated with WTs [29,33–35]. Senanayake et al. [33]
compared the expression of five miRNAs (miR-192, -194, -215, -200c, and -141), each between a
normal kidney and WT of different histological subtypes. They found a significant downregulation
of miR-192, miR-215 and miR-194 in all Wilms tumors irrespective of the subtype, and further a
significant downregulation of miR-141 and miR-200c in blastemal and mixed WTs compared to normal
kidneys [33]. Our findings support this result, as all of these miRNAs were significantly downregulated
21- to 46-fold in our WT set compared to a normal kidney. Kort et al. [34] demonstrated a significant
overexpression of the oncomiR-1 cluster containing miR-17, -18a, -19b, -20a and -92 in WTs compared to
normal kidneys, and an overexpression of several miRNAs, including miR-130b and miR-181b, in WTs
compared to other renal tumors [34]. In our data, we found an overexpression of miR-18a and miR-130b
in blastemal WTs and miR-181b in regressive WTs, each compared to normal kidneys. Furthermore,
we could confirm the overexpression of miR-483-3p in WTs compared to normal kidneys. Previously,
this overexpression was also shown by Veronese et al. [35]. There is also a considerable overlap of
deregulated miRNAs in our study with the study of Watson et al. [29]. The results of Watson et al. [29]
are, however, difficult to compare to our study. Watson et al. [29] compared miRNA expression in the
blastemal component of high-risk patients with either the blastemal or the non-blastemal component
of intermediate risk patients, and did not include normal kidney tissue as a reference. By contrast,
our study focused on the differential expression of miRNA in blastemal (high-risk) and regressive
(intermediate-risk) subtypes in comparison to normal kidneys, and without further information on the
blastemal cell content of our probes. Of the 14 miRNAs reported to be upregulated in the high-risk
blastemal compared to intermediate-risk non-blastemal component, we found that three miRNAs,
namely miR-590-5p, miR-125a-5p and miR-19a, upregulated in blastemal WTs as compared to the
regressive subtype. This analysis comes closest to the comparison of Watson et al. [29]. By contrast, out
of the 17 reported miRNAs that were downregulated in high-risk blastemas, eight were also identified
as deregulated in our study, with six miRNAs showing the opposite direction of deregulation, i.e., an
increased expression in blastemal WTs. Without data on the exact cellular composition of the regressive
tumor samples used in our study, this obvious discrepancy could be attributed to possible residual
blastemal cells in our regressive tumors.
In addition to the previously mentioned miRNAs, we found a strong downregulation of
members of the miR-200 family and of the miR-30 family in both blastemal and regressive WTs.
The downregulation of these miRNA families is associated with epithelial-to-mesenchymal transition,
metastasis and chemoresistance in various cancers [36–39]. On the other hand, we found a marked
upregulation of miR-320c/d/e in all subtypes and, additionally, miR-320a/b in blastemal subtypes.
Regulating Wnt-signaling through its direct target beta-catenin, the overexpression of miR-320 has
been shown to reverse epithelial-to-mesenchymal transition and inhibit stem cell-like properties in
prostate cancer cells [40]. In addition, we detected a significant upregulation of miR-183, -301a/b
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and -335 exclusively in the blastemal subtype. The overexpression of miR-301b is known to promote
invasion and contribute to chemoresistance in pancreatic carcinoma [41]. For the regressive subtype,
we found significant downregulation of miR-195/497 and let-7a/c/d/e/f, and an upregulation of
miRs-223 and -630. We confirmed the upregulation of miRs-181b, -223, and -320a in regressive WTs
compared to normal tissue with RT-qPCR. These miRNAs are involved in modulating chemoresistance
in various cancers [42–47]. For example, the overexpression of miR-223 has been shown to increase
sensitivity to doxorubicin and paclitaxel in hepatocellular carcinoma cells [48], and sensitivity to
cisplatin, mitomycin C and doxorubicin in esophageal adenocarcinoma cells [45]. Increased expression
of miR-181b has been associated with increased chemosensitivity to vincristine and cisplatin in lung
and gastric cancer cell lines [47], and temozolomide in glioblastoma cell lines [46]. To further judge the
role of these miRNAs and their possible relevance to chemotherapy in blastemal vs. regressive WTs, it
will be necessary to determine the cells of origin, i.e., regressive tumor tissue or immune cells, and to
link the abundance of these miRNAs to the clinical outcome in a prospective study.
Several chromosomal aberrations can be found in Wilms tumors, including losses on 1p, 4q, 7p,
9q, 11p, 11q, 14q, 16q, 21q and 22q, and gains on 1q, 3p, 4p, 7q, 8, 12 and 18 [49,50]. In our study,
we performed an enrichment analysis for chromosomal regions enriched for deregulated miRNAs
and genes. As for the chromosomal localization of miRNA precursor genes of deregulated miRNAs,
we found a significant enrichment of downregulated miRNAs on chromosome 1 and chromosome X.
The enrichment of downregulated miRNAs on chromosome 1 might be a consequence of the LOH 1p
or the deletion of distinctive regions on 1p, including the loss of 1p36, which has been observed in
about 10% of Wilms tumors patients [6,50]. In detail, we found downregulation of miRs-200a, -200b
and -429, whose precursors are all located on 1p36.33. The deletion of regions on chromosome X
have also been found in some cases, including Xp11.23 and Xq26.2-26.3 [50]. Downregulated miRNA
with precursors in these regions include miR-363 and miR-424 for Xq26.2-26.3, and miR-362, -500a,
-502, -532, and -660 for Xp11.23. Most interestingly, the latter are organized in a cluster in an intron
of the gene CLCN5 that codes for a voltage-gated chloride ion channel expressed in renal proximal
tubule cells in normal renal tissue. Therefore, downregulation of these miRNAs in Wilms tumors
might be explained by the decreased expression of the ion channel in the tumor tissue. Notably, the
CLCN5 gene is also among the commonly downregulated genes in our data set. In addition, our gene
expression analysis revealed a significant enrichment of downregulated mRNAs on chromosome 4 and
the mitochondrial genome. In total, nine of the 14 protein coding genes encoded on the mitochondrial
genome were downregulated in WTs irrespective of subtype. Moderate to massive downregulation of
mitochondrial mass has been shown for triphasic Wilms tumors, suggestive of a shift from oxidative
phosphorylation activity towards anaerobic glycolysis in WTs [51]. This likely explains the observed
downregulation of mitochondrial genes in WTs in our study. Deletions of distinctive regions or even
the whole chromosome 4 have been reported in Wilms tumor patients [49].
Comparing the mRNA and the miRNA expression data, which are derived from the same tumor,
we found that the overall direction of regulation does not show an inverse correlation between the
miRNome and the transcriptome. By contrast, several of our comparisons show an overall deregulation
of miRNAs and mRNAs in the same direction. For example, the majority of miRNAs (66 of 96) and
the majority of mRNAs (1311 of 2010) were both downregulated in WTs as compared to normal
kidney. Likewise, we found the majority of both miRNAs and mRNAs downregulated in the blastemal
subtype as compared to the controls. These results suggest that the majority of miRNAs does not
induce mRNA degradation. This question awaits further clarification by a simultaneous analysis of
the proteome of the WTs and their subtypes. Besides these overall considerations, the availability of
both miRNA and mRNA from the same origin allowed the search for potential miRNA-target gene
interactions and pathways affected by these interactions. We identified 2844 potential interactions
of 70 deregulated miRNAs, with 854 predicted gene targets with inverse correlation of miRNA and
gene expression, including 36 already validated interactions. Among the predicted interactions was
the interaction between the upregulated gene GLIPR1 and the downregulated miRNAs of the miR-30
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family, i.e., miR-30a/a*/b/c/c-2*/d/e/e*. The overexpression of GLIPR1 is known in Wilms tumors
and occurs with a frequency of 67% [52]. Hypomethylation of the GLIPR1 promoter is even more
common with 87% [52]. Downregulation of the miR-30 family in Wilms tumors might provide a
further mechanism for Wilms tumors to increase GLIPR1 protein expression besides the increased
transcription due to promoter hypomethylation. Additionally, we found an inverse correlation of
miR-204 and the oncogenic transcription factor Meis homeobox 1 (MEIS1), which is consistent with
a previous study showing a downregulation of miR-204 and an overexpression of MEIS1 in a high
proportion of Wilms tumors [53]. This interaction has also been validated with reporter gene and
protein assays [54]. It remains to be seen if the other predicted interactions are relevant for Wilms
tumor genesis, or merely represent coincidental in silico associations. Here, we propose a number
of possible miRNA-gene interactions that might play a role in Wilms tumors and that await further
validation in an experimental setting.
An analysis of KEGG pathways enriched for genes of the interactions predicted by the
overrepresentation analysis in Gene Trail identified three main groups of pathways, including
metabolism, signaling molecules and pathways, and organism systems pathways. The individual
pathways include pathways related to renal function, e.g., “Proximal tubule bicarbonate reclamation”
and to know cancer-related pathways as for example PI3K-Akt signaling. The activation of PI3K-Akt
signaling is a common feature in cancers, resulting in increased proliferation and reduced apoptosis.
Since these pathway associations are derived from mRNA, not from protein data, and mRNA
overexpressing genes are not necessarily overexpressed on protein level, e.g., due to their translational
regulation by miRNAs, further analysis of the proteome will help to dissect the role of the deregulated
miRNome in Wilms tumors.
4. Materials and Methods
4.1. Patient Samples
For identification of specific miRNA profiles in Wilms tumor (WT) tissue, we collected tumor
tissue from 36 patients from the SIOP study including 11 regressive WTs, six mixed WTs, 15 blastemal
WTs, and four other subtypes (stromal, epithelial, diffuse and focal anaplasia). As controls we used four
samples of normal kidney tissue from patients with WTs. Written informed consent was obtained from
all participants. Clinical details of the patients included in the analysis are provided in Supplemental
Table S4. The research was approved by the local ethical committee (No. 136/01; 09/16/2010).
4.2. RNA Isolation
Total RNA including miRNAs was isolated from tumor and control tissues using the miRNeasy
Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. RNA concentration and
integrity were assessed using NanoDrop2000 (Thermo Fisher Scientific, Waltham, MA, USA) and
bioanalyzer run using the PicoRNA Chip (Agilent Technologies, Santa Clara, CA, USA).
4.3. miRNA Expression Profile
The miRNA expression profile of 36 Wilms tumors and four normal kidney controls was measured
using the SurePrint G3 8x60k miRNA microarray (miRBase version 16, Cat. no. G4870A) containing
probes for detection of 1205 mature human miRNAs and the miRNA Complete Labeling and Hyb
Kit (Cat. No. 5190-0456) according to the manufacturers recommendations. Briefly, 100 ng total RNA
including miRNA for each sample was dephosphorylated for 30 min at 37 ˝C using calf intestinal
phophatase, denatured for 10 min at 100 ˝C using 100% dimethyl sulfoxide (DMSO) and subsequently
labeled with Cy3-pCp for 2 h at 16 ˝C using T4 ligase. The labeled RNA for each sample was
hybridized to the microarray for 20 h at 55 ˝C with 20 rpm rotation in the SureHyb chambers (Agilent).
After two washing steps, the arrays were dried and scanned using the Agilent Microarray Scanner
G2565BA (Agilent Technologies, Santa Clara, CA, USA) with 3 µm resolution in double-pass mode.
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Resulting tif-files were analyzed with the Agilent AGW Feature Extraction software (version 10.10.11,
Agilent Technologies). Background corrected values were extracted, log-transformed and quantile
normalized using freely available R software (v.2.14.2, www.r-project.org). We identified differentially
expressed miRNAs in blastemal WTs, regressive WTs and all WT samples combined, each compared
to the four normal kidney samples via an unpaired two-tailed t-test. We considered only miRNAs
differentially expressed, that showed at least a 2-fold decreased or increased mean expression value
and a p-value <0.05 in the t-test. P-values were adjusted using the Benjamini-Hochberg adjustment
method [55]. Raw data has been deposited at GEO database (GSE57370). Unsupervised hierarchical
clustering was performed with the R package heatmap.2 using complete linkage and euclidian distance
applied to the normalized expression matrix using the 50 miRNA with highest variance in the data set.
Venn diagrams were created using Venny 2.1.0 (http://bioinfogp.cnb.csic.es/tools/venny/index.html).
4.4. RT-qPCR Validation
For validation of miRNA array data, we performed quantitative real-time PCR of a total of five
identified differentially regulated miRNAs (miRs-143, -181b, -223, -320a, and -485-3p) and RNU6B as
control on a StepOnePlus Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). The small
RNA RNU6B is widely used as endogenous control in miRNA tissue studies by us and others [56–59].
In short, 100 ng total RNA of each sample (the same as used for array analysis) was used in first strand
synthesis using the miScript II RT Kit (Qiagen) in a total volume of 10 µL using the high-spec buffer.
The resulting complementary DNA (cDNA) was diluted 1:5 and 1 µL of the dilutions were used in
RT-qPCR in a total volume of 10 µL using the miScript SYBR Green PCR Kit and the miScript Primer
Assays (Qiagen) for each miRNA according to manufacturer’s recommendations. Reactions were
performed in duplicates and mean threshold cycle (Ct) values of duplicates were used to calculate ∆Ct
for each miRNA compared to RNU6B in each sample. The mean ∆Ct of each considered group was
calculated and significant expression differences were determined using two-tailed t-test (p < 0.05).
4.5. Gene Expression Profile
The mRNA expression profile of 28 Wilms tumors and four normal kidney controls was
measured with SurePrint G3 Human Gene Expression 8x60Kv2 Microarray (Cat. no. G4851B,
Agilent Technologies, Santa Clara, CA, USA) and the Low Input, one-color, Quick Amp Labeling Kit
(Cat. no. 5190-2305, Agilent Technologies) according to the manufacturers recommendations. Briefly,
100 ng total RNA for each sample was reverse transcribed using Oligo-dT-T7 promotor primers for
2 h at 40 ˝C to obtain cDNA. Labeled cRNA was generated using Cy3-pCp and T7 RNA polymerase
for 2 h at 40 ˝C and subsequently purified using RNeasy Mini kit (Qiagen) according to the protocol
in the Low Input Quick Amp Labeling Kit, One Color, handbook. Purified cRNA was measured
with the NanoDrop2000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) with
the included Microarray Measurement protocol to determine output concentration and to ensure
that labeled cRNA has sufficient quality for hybridization. 600 ng labeled cRNA were hybridized
to the microarray slide for 17 h at 65 ˝C with 10 rpm rotation in the SureHyb chambers (Agilent).
After washing and drying, the array was scanned in the Agilent microarray scanner G2565BA with
5 µm resolution. Resulting tif-files were analyzed with the Agilent AGW Feature Extraction software
(version 10.10.11). Background corrected expression values of all 50,739 features were retrieved,
log-transformed and quantile normalized. Next, we considered only features annotated with a NCBI
gene symbol and calculated the median of replicated measurements of features displaying the same
gene symbol resulting in a normalized expression matrix with 27,908 unique entries. The raw data has
been deposited at GEO database (GSE66405). Unsupervised hierarchical clustering was performed
with the R package heatmap.2 using complete linkage and euclidian distance applied to the normalized
expression matrix using the 50 mRNAs with highest variance in the data set. Venn diagrams were
created using Venny 2.1.0 (http://bioinfogp.cnb.csic.es/tools/venny/index.html).
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4.6. miRNA-mRNA Correlation and Pathway Analysis
For the significantly deregulated 96 miRNAs and 2010 genes in WTs compared to normal tissue,
we computed a Pearson correlation coefficient of expression for each mRNA-miRNA pair using R.
For each potential interaction, defined as Pearson coefficient of the miRNA-mRNA pair <´0.5, we
determined if the mRNA is a predicted or validated target of the miRNA using database searches in
miRWalk (version 1.0) [60] and MirTarBase (release 4.5) [61] , respectively. Additionally, we performed
an overrepresentation analysis of all negatively correlated genes using GeneTrail to analyze which
KEGG pathways are significantly affected by gene expression deregulation in WTs [30].
5. Conclusions
Wilms Tumors exhibit differential miRNA and mRNA expression patterns, depending on their
histological subtypes. It is, however, difficult to determine to what extent a pattern is attributed to
cellular changes induced through chemotherapy or to the respective cell types. Towards a better
understanding of the relationship between miRNA and mRNA expression in Wilms tumor subtypes,
it is mandatory to analyze micro-dissected tumor areas with predominantly epithelial, stromal or
blastemal cells prior to the administration of chemotherapy. Simultaneous analysis of the proteome
will further clarify the downstream effects of the differential miRNA and mRNA expression patterns,
including the effects on cellular pathways in the different cell types.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/
17/4/475/s1.
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